Healthcare Is the New Crowded Trade: What Q2 2026 13Fs Reveal

The Q2 2026 13F filings landed yesterday, and the story buried under the Berkshire headlines is a sector rotation that has been building all summer. Institutional money is moving into healthcare — pharma, managed care, life-sciences tools, medical equipment — at a pace not seen since 2021.

This is not a subtle drift. Goldman Sachs prime brokerage data from late July showed hedge fund bullish exposure to U.S. healthcare stocks at nearly its highest level in five years, with managers adding for a second consecutive week across equipment and supplies, life-sciences tools, and pharmaceuticals. The Q2 filings now give us the position-level detail behind that flow.

The numbers behind the rotation

Three data points frame how serious this is.

First, performance. Specialist healthcare hedge funds returned roughly 40% between August 2025 and April 2026, against about 17% for generalist equity funds. When one corner of the market triples the return of the average, capital follows.

Second, fund formation. Goldman reported that 24% of new hedge funds launched in 2026 were dedicated to healthcare — the highest proportion since at least 2009. Healthcare specialists now manage roughly $283 billion of the approximately $1 trillion overseen by equity hedge funds.

Third, deal flow. Goldman estimates healthcare M&A volume could reach $173 billion in 2026, the highest annual level since 2019. Funds are not just buying the sector's earnings — they are positioning for takeouts.

What the filings actually show

The names appearing repeatedly across Q2 13Fs skew large-cap and defensive rather than speculative biotech: Eli Lilly, UnitedHealth Group, Johnson & Johnson, and Elevance Health. That composition matters. This is not a 2021-style small-cap biotech melt-up funded by cheap money. It is a rotation into cash-generative businesses with visible earnings, which reads more like a defensive repositioning than a risk-on bet.

Eli Lilly remains the anchor. Q1 2026 sales rose 56% year over year on Mounjaro (up 125%) and Zepbound (up 80%), and the phase 3 data on triple agonist retatrutide extended the revenue visibility window toward a 2027 launch. When a mega-cap compounds revenue at that rate, it stops being a healthcare position and starts being a core holding.

UnitedHealth is the more interesting tell. It spent much of the past two years as a battleground name, and several funds that exited during the drawdown have quietly rebuilt. You can trace that reversal directly in the holdings history on InvestorLens — which managers sold, when, and who came back.

Why now

Two forces are pushing in the same direction.

The obvious one is AI valuation fatigue. July delivered a sharp unwind in crowded AI and semiconductor positions, and money that came out of those names had to go somewhere. Healthcare offered reasonable multiples, dividend support, and low correlation to the GPU capex cycle.

The less obvious one is that AI is now a reason to own healthcare rather than a competitor for capital. Goldman noted improving research productivity as AI increasingly supports drug development. Funds that spent 2024 and 2025 buying the picks-and-shovels of AI infrastructure are now buying the companies expected to monetize the output. You can see how those two exposures have traded places over recent quarters on the sector flow view.

The crowding problem

Here is the part that should give you pause. Every characteristic that makes this trade attractive — strong recent returns, heavy new fund formation, concentrated positioning in a handful of large caps — is also the standard profile of a crowded trade approaching its uncomfortable phase.

Crowding is not a sell signal on its own. Crowded trades can run for years. But crowding does change the risk profile: it means a disappointing trial readout, an adverse policy headline, or a single large fund unwinding produces a bigger price move than the news alone justifies, because the same holders are reaching for the same exit.

The practical response is to measure it rather than guess. Our overlap tool shows how many tracked institutions hold a given name and how concentrated their combined exposure is. A healthcare position held by six funds with modest weightings is a very different risk than the same position held by thirty funds at high conviction.

Reading it in context

One structural caveat applies to everything above. These filings describe positions as of June 30 — six and a half weeks ago. A manager who added to healthcare in early July does not appear here. A manager who has already taken profits still shows as a holder. The 13F is a lagged photograph, not a live feed.

That said, the direction of travel is corroborated by independent prime brokerage data from July, which is the strongest confirmation a lagged dataset can get. When the 45-day-old filings and the two-week-old flow data agree, the signal is real even if the exact entry points are stale.

For the broader picture of how this fits with positioning in rates, energy, and technology, the macro consensus view aggregates the directional read across every investor we track.

---

Data sourced from public SEC 13F filings. Educational research only — not investment advice.